Patent intelligence · US
US 11179394
Method for treating cancer using a combination of Chk1 and ATR inhibitors
Method for treating cancer using a combination of Chk1 and ATR inhibitors
Patent details — US 11179394
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 23, 2021
- Expiration
- Nov 18, 2041
- Applicant
- Vertex Pharmaceuticals Incorporated
- Claims
- 17
- CPC classes
- A61K, A61K31/4535, A61K31/4709, A61K31/4965
Quick answer
US 11179394 (Method for treating cancer using a combination of Chk1 and ATR inhibitors) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Nov 23, 2021. Expires Nov 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/4535, A61K31/4709, A61K31/4965, A61K31/497, A61K31/4985
More from Vertex Pharmaceuticals Incorporated
Related pharmaceutical patents in our USPTO index.
-
US 12421251
Cystic fibrosis transmembrane conductance regulator modulating agents
granted -
US 12421249
Inhibitors of APOL1 and methods of using same
granted -
US 12384790
Pteridinone compounds and uses thereof
granted -
US 12384762
Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
granted -
US 12385013
Differentiation of pancreatic endocrine cells
granted -
US 12377252
Implantation devices, system, and methods
granted -
US 12371665
Differentiation of pancreatic endocrine cells
granted -
US 12350262
Methods of treatment for cystic fibrosis
granted
Frequently asked questions
What is US patent 11179394?
US 11179394 (Method for treating cancer using a combination of Chk1 and ATR inhibitors) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Nov 23, 2021. Expires Nov 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11179394?
Vertex Pharmaceuticals Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 991 pharmaceutical patents for this assignee.
When does US 11179394 expire?
Our index shows an expiration date of Nov 18, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.